<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125918</url>
  </required_header>
  <id_info>
    <org_study_id>10303</org_study_id>
    <secondary_id>H6D-MC-LVGY</secondary_id>
    <nct_id>NCT00125918</nct_id>
  </id_info>
  <brief_title>PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension</brief_title>
  <official_title>PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICOS Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the
      treatment of pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter study. The key measure of
      effectiveness of the study drug will be determined using a 6-minute walk test. Eligible
      patients will be treated for 16 weeks and may be eligible to enter a 52-week extension phase
      study (PHIRST-2). Study procedures for both studies (PHIRST-1 and PHIRST-2) will include
      routine blood tests, medical history, physical exams, questionnaire responses, and exercise
      tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk distance change from baseline to Week 16</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>World Health Organization (WHO) functional class, Borg dyspnea, cardiopulmonary hemodynamics, quality of life - change from baseline to Week 16</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of clinical worsening</measure>
    <time_frame>Not defined</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg tadalafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg tadalafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg tadalafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg tadalafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablet taken by mouth once a day for 16 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 12 years of age.

          -  Body weight at least 40 kg (approximately 88 pounds).

          -  Pulmonary hypertension (PAH) that is either idiopathic; related to collagen vascular
             disease; related to anorexigen use; associated with an atrial septal defect (resting
             SaO2 greater than or equal to 88%); with surgical repair, of at least 1 year duration,
             of a congenital systemic-to-pulmonary shunt.

          -  If on bosentan, must be at the maximal dose of 125 mg twice daily for a minimum of 12
             weeks prior to screening and have an AST/ALT less than 3 times normal.

          -  History of PAH established by a resting mean pulmonary artery pressure greater than or
             equal to 25 mm Hg, pulmonary artery wedge pressure less than or equal to 15 mm Hg, and
             pulmonary vascular resistance greater than or equal to 3 Wood units via right heart
             catheterization

          -  Have World Health Organization functional class I, II, III or IV status.

          -  Have a qualifying 6-minute walk test distance at screening

          -  Have no evidence of significant parenchymal lung disease

        Exclusion Criteria:

          -  Are nursing or pregnant.

          -  PAH due to conditions other than noted in the above inclusion criteria.

          -  History of left-sided heart disease.

          -  History of atrial septostomy within 3 months before study entry

          -  History of angina pectoris or other condition that was treated with long-or
             short-acting nitrates within 12 weeks before administration of study drug.

          -  History of symptomatic coronary disease.

          -  Have any therapy with a prostacyclin or analogue, L-arginine, phosphodiesterase (PDE)
             inhibitor, or investigational drug within 4 weeks before administration of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.phassociation.org</url>
    <description>The Pulmonary Hypertension Association (PHA) is an organization that provides support, education, advocacy, and awareness about pulmonary hypertension.</description>
  </link>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <last_update_submitted>February 13, 2008</last_update_submitted>
  <last_update_submitted_qc>February 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2008</last_update_posted>
  <keyword>Hypertension, Pulmonary; Pulmonary Heart Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

